Progress towards the use of HIV protease inhibitors in cancer therapy

Cancer Biology and Therapy

Volumn 7, Issue 5, 2008, Pages 636-637

  Bernhard, Eric J ^a   Brunner, Thomas B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

AKT; HIV protease inhibitors; Nelfinavir; Proteasome; Radiation

Indexed keywords

NELFINAVIR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEINASE INHIBITOR; RADIOSENSITIZING AGENT; TUMOR MARKER;

CLINICAL TRIAL; HUMAN; METABOLISM; MONONUCLEAR CELL; NEOPLASM; NOTE; VIROLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CLINICAL TRIALS AS TOPIC; HIV PROTEASE INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; NELFINAVIR; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION-SENSITIZING AGENTS; TUMOR MARKERS, BIOLOGICAL;

EID: 56149098133     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.5.6087     Document Type: Note

References (18)

1. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat Rev Cancer 2004; 4:861-75. (Pubitemid 39472953)
2. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13:5183-94. (Pubitemid 47502088)
3. Plastaras J, Vapiwala N, Ahmed M, Gudonis D, Cerniglia G, Feldman M, Frank I, Gupta A. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther 2008; 7:628-35.
4. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005; 65:8256-65. (Pubitemid 41330590)
5. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002; 62:5230-5. (Pubitemid 35024595)
6. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, Cusack JC Jr. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NFkappaB. Int J Radiat Oncol Biol Phys 2001; 50:183-93.
7. Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia (New York) 2007; 9:271-8. (Pubitemid 46608294)
8. Pajonk F, Grumann T, McBride WH. The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation. Neoplasia (New York) 2006; 8:1037-41. (Pubitemid 44936153)
9. Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, Koch CJ, Hahn SM, Maity A. Nelfinavir downregulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006; 66:9252-9. (Pubitemid 44521147)
10. Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia (New York) 2006; 8:889-95.
11. Birle DC, Hedley DW. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 2007; 67:1735-43. (Pubitemid 46383400)
12. Orlowski R, Kuhn D. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res 2008; 14:1649-57. (Pubitemid 351469448)
13. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24:9695-704. (Pubitemid 39458799)
14. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-28. (Pubitemid 32708698)
15. Weber CN, Cerniglia GJ, Maity A, Gupta AK. Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biol Ther 2007; 6:156-9. (Pubitemid 46641617)
16. Davies A, Lara P, Mack P, Gandara D. Incorporating Bortezomib into the Treatment of Lung Cancer. Clin Cancer Res 2007; 13:4647-51.
17. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA, Conley BA. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 63:1400-12. (Pubitemid 41628035)
18. Brunner T, Geiger M, Grabenbauer G, Lang-Welzenbach M, Mantoni T, Cavallaro A, Sauer R, Hohenberger W, McKenna W. A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008; 26:2699-706.